Current Opinion in Investigational Drugs
Archive
Current Opinion in Investigational Drugs, Volume 2
Paper alert LJ Hofseth, D Witty, S Doggrell, Gasparo M de, D Lane, M Williams, ME Hurst, G Damia, M Daneshtalab, A Palmer, B Leonard Current Opinion in Investigational Drugs 2001, 2 :1-13 (5 [Abstract ] [Full text ] [PDF ]
Patent alert WM Brown, HAM Mucke, P Norman Current Opinion in Investigational Drugs 2001, 2 :14-34 (5 [Abstract ] [Full text ] [PDF ]
The use of CpG DNA as a mucosal vaccine adjuvant MJ McCluskie, RD Weeratna, PJ Payette, HL Davis Current Opinion in Investigational Drugs 2001, 2 :35-39 (5 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Towards the development of vaccines against Helicobacter pylori: Status and issues Giudice G Del Current Opinion in Investigational Drugs 2001, 2 :40-44 (5 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Overview. Vaccines: Ideal drugs for the 21st century? R Rappuoli, G Nabel Current Opinion in Investigational Drugs 2001, 2 :45-46 (5 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Menjugate DH Jones Current Opinion in Investigational Drugs 2001, 2 :47-49 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Tetracel DH Jones Current Opinion in Investigational Drugs 2001, 2 :50-52 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Inhaled anticholinergic therapy: Applied pharmacology and interesting developments TJ Witek, B Disse Current Opinion in Investigational Drugs 2001, 2 :53-58 (5 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Neutrophil-derived elastases and their inhibitors: Potential role in the pathogenesis of lung disease PT Reid, J-M Sallenave Current Opinion in Investigational Drugs 2001, 2 :59-67 (5 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
ABT-761 DH Jones Current Opinion in Investigational Drugs 2001, 2 :68-71 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Inhibition of cardiac ATP-dependent potassium channels by sulfonylurea drugs H G Current Opinion in Investigational Drugs 2001, 2 :72-80 (5 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Therapy of heart failure T Ecder, D Korular, AK Gurevich, HD Weinberger, RW Schrier Current Opinion in Investigational Drugs 2001, 2 :81-86 (5 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
New antiarrhythmic agents for atrial fibrillation DSG Conway, GYH Lip Current Opinion in Investigational Drugs 2001, 2 :87-92 (5 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
KCB-328 G Billman Current Opinion in Investigational Drugs 2001, 2 :93-96 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Tedisamil NA Flores Current Opinion in Investigational Drugs 2001, 2 :97-103 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
The therapeutic potential of 5-HT6 receptor antagonists C Reavill, DC Rogers Current Opinion in Investigational Drugs 2001, 2 :104-109 (5 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Cost effectiveness of the newer atypical antipsychotics: A review of the pharmacoeconomic research evidence DA Revicki Current Opinion in Investigational Drugs 2001, 2 :110-117 (5 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
SB-271046 Hidalgo MJ Miguel Current Opinion in Investigational Drugs 2001, 2 :118-122 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
M-100907 Paulis T de Current Opinion in Investigational Drugs 2001, 2 :123-132 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Overview. Humoral and cellular immune responses: Independent forces or collaborators in the fight against cancer? RT Reilly, LA Emens, EM Jaffee Current Opinion in Investigational Drugs 2001, 2 :133-135 (5 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Endothelial monocyte activating polypeptide II (EMAP II) enhances the effect of TNF on tumor-associated vasculature ML Kayton, SK Libutti Current Opinion in Investigational Drugs 2001, 2 :136-138 (5 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Alemtuzumab FJ Dumont Current Opinion in Investigational Drugs 2001, 2 :139-160 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Paper alert M Daneshtalab, T Jones, S Doggrell, Gasparo M de, D Lane, M Williams, E Boven, RE Hurst Current Opinion in Investigational Drugs 2001, 2 :161-172 (13 [Abstract ] [Full text ] [PDF ]
Patent alert OA Phillips, WM Brown, HAM Mucke, P Norman Current Opinion in Investigational Drugs 2001, 2 :173-197 (13 [Abstract ] [Full text ] [PDF ]
Preclinical candidates and targets for tuberculosis therapy III CE Barry Current Opinion in Investigational Drugs 2001, 2 :198-201 (13 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
MEN-10700 (Menarini) N Jiraskova Current Opinion in Investigational Drugs 2001, 2 :202-204 (13 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Anti-MRSA cephalosporins (Bristol-Myers Squibb) AP Johnson Current Opinion in Investigational Drugs 2001, 2 :205-208 (13 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
RWJ-333441 (Microcide/RW Johnson) N Jiraskova Current Opinion in Investigational Drugs 2001, 2 :209-211 (13 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
MC-207110 (Daiichi Seiyaku/Microcide Pharmaceuticals) JF Barrett Current Opinion in Investigational Drugs 2001, 2 :212-215 (13 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Etanercept (Immunex). RL Yung Current Opinion in Investigational Drugs 2001, 2 :216-221 (13 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Leflunomide (Aventis Pharma). MJ Kaplan Current Opinion in Investigational Drugs 2001, 2 :222-230 (13 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
GL-701 (Genelabs). P Norman Current Opinion in Investigational Drugs 2001, 2 :231-236 (13 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Therapeutic approaches to childhood acquired aplastic anemia. K Sugita Current Opinion in Investigational Drugs 2001, 2 :237-243 (13 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Basic and clinical aspects of platelet integrin alphallbbeta3 receptor antagonists in acute coronary syndromes. JA Goudevenos, AD Tselepis Current Opinion in Investigational Drugs 2001, 2 :244-249 (13 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Cangrelor (AstraZeneca). SC Chattaraj Current Opinion in Investigational Drugs 2001, 2 :250-255 (13 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Overview: Where are all the novel antidepressants? E Richelson Current Opinion in Investigational Drugs 2001, 2 :256-258 (13 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Drug mechanisms in anxiety. M Bourin, M Hascoet Current Opinion in Investigational Drugs 2001, 2 :259-265 (13 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Siramesine (H Lundbeck). C Heading Current Opinion in Investigational Drugs 2001, 2 :266-270 (13 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
(S)-Zopiclone (Sepracor). V Georgiev Current Opinion in Investigational Drugs 2001, 2 :271-273 (13 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
CRF antagonists (DuPont). A Preti Current Opinion in Investigational Drugs 2001, 2 :274-279 (13 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Receptor tyrosine kinase inhibitors. P Haluska, AA Adjei Current Opinion in Investigational Drugs 2001, 2 :280-286 (13 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
UCN-01 (Kyowa Hakko Kogyo Co). K Grosios Current Opinion in Investigational Drugs 2001, 2 :287-297 (13 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
OSI-774 (Pfizer). P Norman Current Opinion in Investigational Drugs 2001, 2 :298-304 (13 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Paper alert M Daneshtalab, S Doggrell, D Lane, M Gasparo, F Barone, P Smith, B Leonard, G Damia, LJ Hofseth, RE Hurst Current Opinion in Investigational Drugs 2001, 2 :305-319 (16 [Abstract ] [Full text ] [PDF ]
Patent alert W Brown, HAM Mucke, P Norman Current Opinion in Investigational Drugs 2001, 2 :320-334 (16 [Abstract ] [Full text ] [PDF ]
Mechanisms of HIV-1 nucleoside reverse transcriptase inhibitor resistance: Is it all figured out? LK Naeger, MD Miller Current Opinion in Investigational Drugs 2001, 2 :335-339 (16 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
BMS-232632 Novartis/Bristol-Myers Squibb. G Witherell Current Opinion in Investigational Drugs 2001, 2 :340-347 (16 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
DAPD Emory University/Triangle Pharmaceuticals/Abbott Laboratories. AH Corbett, JC Rublein Current Opinion in Investigational Drugs 2001, 2 :348-353 (16 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
TAK-779 Takeda. JA Est Current Opinion in Investigational Drugs 2001, 2 :354-356 (16 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Treatment of transplant rejection: Are the traditional immunosuppressants good enough? FJ Dumont Current Opinion in Investigational Drugs 2001, 2 :357-363 (16 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
TP-10 AVANT Immunotherapeutics. P Rioux Current Opinion in Investigational Drugs 2001, 2 :364-371 (16 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Tresperimus Laboratoires Fournier. MJ Elices Current Opinion in Investigational Drugs 2001, 2 :372-374 (16 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Reverse cholesterol transport and future pharmacological approaches to the treatment of atherosclerosis. BR Krause, BJ Auerbach Current Opinion in Investigational Drugs 2001, 2 :375-381 (16 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
A clinical focus on statins. J Auer, B Eber Current Opinion in Investigational Drugs 2001, 2 :382-388 (16 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
Ezetimibe Schering-Plough. CQ Meng Current Opinion in Investigational Drugs 2001, 2 :389-392 (16 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
S-8921 Shionogi. ML Booker Current Opinion in Investigational Drugs 2001, 2 :393-395 (16 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Overview: Differential gene expression - how to find new analgesic targets. K Befort, M Costigan, CJ Woolf Current Opinion in Investigational Drugs 2001, 2 :396-398 (16 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Cannabinoids and pain. ASC Rice Current Opinion in Investigational Drugs 2001, 2 :399-414 (16 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Donitriptan Pierre Fabre. M Dukat Current Opinion in Investigational Drugs 2001, 2 :415-418 (16 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
MT-500 POZEN. HAM Mucke Current Opinion in Investigational Drugs 2001, 2 :419-421 (16 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Overview: Recent success with the tyrosine kinase inhibitor STI-571 - lessons for targeted therapy of cancer. NP Shah, CL Sawyers Current Opinion in Investigational Drugs 2001, 2 :422-423 (16 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
CT-2584 Cell Therapeutics. RD Bonfil Current Opinion in Investigational Drugs 2001, 2 :424-427 (16 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
ZD-1839 AstraZeneca. P Norman Current Opinion in Investigational Drugs 2001, 2 :428-435 (16 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Editorial: Genomics, proteomics and gnomics M Williams Current Opinion in Investigational Drugs 2001, 2 :437-439 (6 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
Paper alert D Witty, T Jones, Gasparo M de, M Williams, B Leonard, P Smith, E Boven, RE Hurst Current Opinion in Investigational Drugs 2001, 2 :440-446 (6 [Abstract ] [Full text ] [PDF ]
Patent selection M Mucke Current Opinion in Investigational Drugs 2001, 2 :447-450 (6 [Abstract ] [Full text ] [PDF ]
Patent alert OA Phillips, WM Brown, HAM Mucke, P Norman Current Opinion in Investigational Drugs 2001, 2 :451-467 (6 [Abstract ] [Full text ] [PDF ]
Overview: Hitting a new target with echinocandins. Why chase something else? JR Graybill Current Opinion in Investigational Drugs 2001, 2 :468-471 (6 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Antifungal antibodies: A new approach to the treatment of systemic candidiasis R Matthews, J Burnie Current Opinion in Investigational Drugs 2001, 2 :472-476 (6 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Killer anti-idiotypes in the control of fungal infections W Magliani, C Stefania, S Arseni, R Frazzi, A Salati, L Polonelli Current Opinion in Investigational Drugs 2001, 2 :477-479 (6 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Nystatin LF (Aronex/Abbott) S Arikan, JH Rex Current Opinion in Investigational Drugs 2001, 2 :480-487 (6 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
A novel heparin-coated hydrophilic preparation of amphotericin B Hydrosomes KV Clemons, DF Ranney, DA Stevens Current Opinion in Investigational Drugs 2001, 2 :480-487 (6 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Inflammatory mediators as therapeutic targets in acute pancreatitis M Bhatia, JP Neoptolemos, J Slavin Current Opinion in Investigational Drugs 2001, 2 :496-501 (6 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
LDP-02 (Millennium) JK Marshall Current Opinion in Investigational Drugs 2001, 2 :502-504 (6 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
ALX-0600 (NPS Allelix Corp) DL Sigalet Current Opinion in Investigational Drugs 2001, 2 :505-509 (6 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
IS-741 (Ishihara Sangyo) C Bassi Current Opinion in Investigational Drugs 2001, 2 :510-512 (6 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Endothelin antagonists in the treatment of renal failure. DM Pollock Current Opinion in Investigational Drugs 2001, 2 :513-520 (6 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Eplerenone (GD Searle) J Martin, H Krum Current Opinion in Investigational Drugs 2001, 2 :521-524 (6 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Lixivaptan (American Home Products) A Martinez-Castelao Current Opinion in Investigational Drugs 2001, 2 :525-530 (6 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Sitaxsentan (ICOS-Texas Biotechnology) JR Wu-Wong Current Opinion in Investigational Drugs 2001, 2 :531-536 (6 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Overview: Corticotropin releasing factor antagonists - the new anti-anxiety magic bullets? WW Blessing Current Opinion in Investigational Drugs 2001, 2 :537-538 (6 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
5-Hydroxytryptamine and the gastrointestinal migrating motor complex MA Plaza Current Opinion in Investigational Drugs 2001, 2 :539-544 (6 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Aviptadil (Senetek) GBJM Keijzers Current Opinion in Investigational Drugs 2001, 2 :545-549 (6 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Alibra (VIVUS) AA Qureshi Current Opinion in Investigational Drugs 2001, 2 :550-554 (6 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
GM-611 (Chugai Pharmaceutical) TL Peeters Current Opinion in Investigational Drugs 2001, 2 :555-557 (6 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Application of PNA and LNA oligomers to chemotherapy AN Elayadi, DR Corey Current Opinion in Investigational Drugs 2001, 2 :558-561 (6 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides RS Geary, RZ Yu, AA Levin Current Opinion in Investigational Drugs 2001, 2 :562-571 (6 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Genasense (Genta Inc) D Banerjee Current Opinion in Investigational Drugs 2001, 2 :574-580 (6 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Paper alert D Witty, Gasparo M de, M Williams, C Darlington, E Boven, G Damia, RE Hurst Current Opinion in Investigational Drugs 2001, 2 :581 (17 [Abstract ] [Full text ] [PDF ]
Patent selection H Mucke Current Opinion in Investigational Drugs 2001, 2 :592 (17 [Abstract ] [Full text ] [PDF ]
Patent alert OA Phillips, IB Duncan, WM Brown, HAM Muckle, P Norman Current Opinion in Investigational Drugs 2001, 2 :595 (17 [Abstract ] [Full text ] [PDF ]
Prevention of viral drug resistance by novel combination therapy. WF Mangel, MT Brown, ML Baniecki, D Barnard, WJ McGrath Current Opinion in Investigational Drugs 2001, 2 :613 (17 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Entecavir (Bristol-Myers Squibb). A Billich Current Opinion in Investigational Drugs 2001, 2 :617 (17 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Genvir (Flamel Technologies). DL Barnard Current Opinion in Investigational Drugs 2001, 2 :622 (17 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Overview: Shifting attention from one cell type to another in dermatological research, but where are the new drugs? C Korstanje Current Opinion in Investigational Drugs 2001, 2 :624 (17 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Retinoids for the treatment of psoriasis: Outlook for the future S Kuenzil, J-H Saurat Current Opinion in Investigational Drugs 2001, 2 :625 (17 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Alefacept (Biogen). SJ Bashir, HI Maibach Current Opinion in Investigational Drugs 2001, 2 :631 (17 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
IDEC-114 (IDEC) RE Schopf Current Opinion in Investigational Drugs 2001, 2 :635 (17 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Cell therapy approaches for the treatment of diabetes. S Efrat Current Opinion in Investigational Drugs 2001, 2 :639 (17 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Treatment of gynecomastia. U Gruntmanis, GD Braunstein Current Opinion in Investigational Drugs 2001, 2 :643 (17 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
CLX-0901 (Calyx Therapeutics) D Barlocco Current Opinion in Investigational Drugs 2001, 2 :650 (17 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Overview: Therapeutic strategies to retard neuronal cell death in neurodegenerative diseases. RE Davis Current Opinion in Investigational Drugs 2001, 2 :654 (17 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Pathogenesis of Parkinson's disease. TB Sherer, R Betarbet, T Greenamyre Current Opinion in Investigational Drugs 2001, 2 :657 (17 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
AN-1792 (Elan). U Thattle Current Opinion in Investigational Drugs 2001, 2 :663 (17 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
KW-6002 (Kyowa Hakko Kogyo). LJS Knutsen Current Opinion in Investigational Drugs 2001, 2 :668 (17 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Overview: Developing novel and highly effective new therapeutic strategies for treatment of colorectal cancer: Where do we go from here? JA Houghton Current Opinion in Investigational Drugs 2001, 2 :674 (17 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Sulindac and its derivatives: A novel class of anticancer agents. C Haanen Current Opinion in Investigational Drugs 2001, 2 :677 (17 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Apoptosis modulators as cancer therapeutics. LZ Penn Current Opinion in Investigational Drugs 2001, 2 :684 (17 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Thymitaq (Zarix). I Niculescu-Duvaz Current Opinion in Investigational Drugs 2001, 2 :693 (17 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Paper alert T Jones, M Daneshtalab, S Doggrell, F Barone, M Williams, B Leonard, A Palmer, C Darlington, P Smith, E Boven, D Giovanna, RE Hurst Current Opinion in Investigational Drugs 2001, 2 :707-724 (20 [Abstract ] [Full text ] [PDF ]
Patent selection HAM Mucke Current Opinion in Investigational Drugs 2001, 2 :725-729 (20 [Abstract ] [Full text ] [PDF ]
Patent alert WM Brown, HAM Mucke, P Norman Current Opinion in Investigational Drugs 2001, 2 :730-741 (20 [Abstract ] [Full text ] [PDF ]
Overview: Perspectives on genomics and antibiotic discovery. J Trias Current Opinion in Investigational Drugs 2001, 2 :742-744 (18 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Antibacterial agents (oxazolidinones, quinolones, macrolides and new agents): Patent highlights June to December 2000. OA Phillips, WC Matowe Current Opinion in Investigational Drugs 2001, 2 :745-751 (18 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
RU-79115 (Aventis Pharma). SC Annedi, LP Kotra Current Opinion in Investigational Drugs 2001, 2 :752-754 (18 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Tobramycin (Cystic Fibrosis Foundation/PathoGenesis). MP Singh Current Opinion in Investigational Drugs 2001, 2 :755-765 (9 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
ABT-773 (Abbott). LE Lawrence Current Opinion in Investigational Drugs 2001, 2 :766-772 (20 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
ABT-773 Abbott Laboratories LE Lawrence Current Opinion in Investigational Drugs 2001, 2 :766 (18 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
The CD40-CD40 ligand system: A potential therapeutic target in atherosclerosis. RP Phipps, L Koumas, E Leung, SY Reddy, T Blieden, J Kaufman Current Opinion in Investigational Drugs 2001, 2 :773-777 (18 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Macrophage migration inhibitory factor as a target molecule in multiple sclerosis. J Nishihira, A Ogata Current Opinion in Investigational Drugs 2001, 2 :778-782 (18 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
New developments in the treatment of ischemia/reperfusion injury. Robichaud A Fox, HK Ondiveeran Current Opinion in Investigational Drugs 2001, 2 :783-791 (18 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
AdGVVEGF121.10 (GenVec). N Basara Current Opinion in Investigational Drugs 2001, 2 :792-795 (18 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
VEGF-2 (St Elizabeth's Medical Center). PKF Yeung Current Opinion in Investigational Drugs 2001, 2 :796-800 (18 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Acute spinal cord injury: Pharmacotherapy and drug development perspectives. AR Blight, MP Zimber Current Opinion in Investigational Drugs 2001, 2 :801-808 (18 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Safinamide (Newron Pharmaceuticals). PL Chazot Current Opinion in Investigational Drugs 2001, 2 :809-813 (18 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Gacyclidine (Beaufour-Ipsen). APA Mitha, KI Maynard Current Opinion in Investigational Drugs 2001, 2 :814-819 (18 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
BMS-204352 (Bristol-Myers Squibb). KB Mackay Current Opinion in Investigational Drugs 2001, 2 :820-823 (18 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Soretolide (Laboratoires Biocodex). MO Fatope Current Opinion in Investigational Drugs 2001, 2 :824-827 (18 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Pregabalin (Pfizer). I Selak Current Opinion in Investigational Drugs 2001, 2 :828-834 (18 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Overview: Gene-directed enzyme prodrug therapy (GDEPT) - recognizing the present limitations of gene therapy for the treatment of cancer. RJ Knox Current Opinion in Investigational Drugs 2001, 2 :835-838 (18 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Use of hypoxia-regulated gene expression in tumor-specific gene therapy. DF Deen, H Ruan Current Opinion in Investigational Drugs 2001, 2 :839-843 (18 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
GVAX (Cell Genesys). R Dummer Current Opinion in Investigational Drugs 2001, 2 :844-848 (18 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Paper alert M Daneshtalab, D Witty, S Doggrell, D Lane, M Williams, RE Hurst Current Opinion in Investigational Drugs 2001, 2 :849-863 (11 [Abstract ] [Full text ] [PDF ]
Patent selection HAM Mucke Current Opinion in Investigational Drugs 2001, 2 :864-867 (11 [Abstract ] [Full text ] [PDF ]
Patent alert IB Duncan, WM Brown, P Norman, HAM Mucke Current Opinion in Investigational Drugs 2001, 2 :868-889 (11 [Abstract ] [Full text ] [PDF ]
PIV-3 Vaccine (National Institutes of Health/Aviron). T Jones Current Opinion in Investigational Drugs 2001, 2 :890-892 (11 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Rotavirus vaccine (AVANT/GlaxoSmithKline). T Jones Current Opinion in Investigational Drugs 2001, 2 :893-895 (11 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Helivax (Antex Biologics). GD Giudice Current Opinion in Investigational Drugs 2001, 2 :896-899 (11 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Anti-inflammatory approaches to the treatment of cystic fibrosis lung disease: Past, present and future CM Oermann Current Opinion in Investigational Drugs 2001, 2 :900-906 (11 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
Targeting selectins for the treatment of respiratory diseases SJ Romano, DH Slee Current Opinion in Investigational Drugs 2001, 2 :907-913 (11 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
CpG oligodeoxynucleotides in asthma I Hussain, JN Kline Current Opinion in Investigational Drugs 2001, 2 :914-918 (11 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Nepadutant (Menarini Richerche). A Ahluwalia Current Opinion in Investigational Drugs 2001, 2 :919-922 (11 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
New pharmacological strategies for the treatment of heart failure BSP Chin, GYH Lip Current Opinion in Investigational Drugs 2001, 2 :923-928 (11 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
BNP in decompensated heart failure: Diagnostic, prognostic and therapeutic potential MR Burger, AJ Burger Current Opinion in Investigational Drugs 2001, 2 :929-935 (11 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
JTV-519 (Japan Tobacco). HF Tse, WF Lam Current Opinion in Investigational Drugs 2001, 2 :936-939 (11 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Use of atypical antipsychotics in mood disorders R Weizman, A Weizman Current Opinion in Investigational Drugs 2001, 2 :940-945 (11 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
SB-277011 (GlaxoSmithKline). G Remington, S Kapur Current Opinion in Investigational Drugs 2001, 2 :946-949 (11 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Osanetant (Sanofi-Synthelabo). F Kamali Current Opinion in Investigational Drugs 2001, 2 :950-956 (11 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Immunotherapy for cancer: Focusing on developing treatments rather than drugs M Sznol Current Opinion in Investigational Drugs 2001, 2 :957-958 (11 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Immunization against tumor cell surface complement-regulatory proteins LG Durrant, I Spendlove Current Opinion in Investigational Drugs 2001, 2 :959-966 (11 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Small-molecule cytokine inducers causing tumor necrosis BC Baguley Current Opinion in Investigational Drugs 2001, 2 :967-975 (11 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Leuvectin (Vical Inc). A Kaushik Current Opinion in Investigational Drugs 2001, 2 :976-981 (11 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Paper alert M Daneshtalab, M Elices, S Doggrell, M Gasparo, M Williams, C Darlington, P Smith, E Boven, G Damia, RE Hurst Current Opinion in Investigational Drugs 2001, 2 :983-1002 (8 [Abstract ] [Full text ] [PDF ]
Patent selection HAM Mucke Current Opinion in Investigational Drugs 2001, 2 :1003-1006 (8 [Abstract ] [Full text ] [PDF ]
Patent alert OA Phillips, P Norman, WM Brown, HAM Mucke Current Opinion in Investigational Drugs 2001, 2 :1007-1027 (8 [Abstract ] [Full text ] [PDF ]
Delivering novel targets and antibiotics from genomics. D Payne, DJ Holmes, M Rosenberg Current Opinion in Investigational Drugs 2001, 2 :1028-1034 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
THF carbapenems (Wyeth Ayerst). N Jiraskova Current Opinion in Investigational Drugs 2001, 2 :1035-1038 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Oritavancin (Eli Lilly & Co). JF Barrett Current Opinion in Investigational Drugs 2001, 2 :1039-1044 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Novel therapies in the treatment of systemic lupus erythematosus. CR Dequet, DJ Wallace Current Opinion in Investigational Drugs 2001, 2 :1045-1053 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Angiogenesis: A therapeutic target in arthritis. DA Walsh, L Haywood Current Opinion in Investigational Drugs 2001, 2 :1054-1063 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Arthritic diseases: Melanocortin type 3 receptor agonists as potential therapeutics. SJ Getting, M Perretti Current Opinion in Investigational Drugs 2001, 2 :1064-1069 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
VX-745 (Vertex Pharmaceuticals). JJ Haddad Current Opinion in Investigational Drugs 2001, 2 :1070-1076 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
Overview: From heparin to low molecular weight heparin: Beyond anticoagulation. SA Mousa, J Fareed Current Opinion in Investigational Drugs 2001, 2 :1077-1080 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
The potential of erythropoietin and related strategies to stimulate erythropoiesis. KU Eckardt Current Opinion in Investigational Drugs 2001, 2 :1081-1085 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Antiplatelet therapies: Platelet GPIIb/IIIa antagonists and beyond. K Konstantopoulos, SA Mousa Current Opinion in Investigational Drugs 2001, 2 :1086-1092 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
YM-337 (Yamanouchi). S Kamath, GYH Lip Current Opinion in Investigational Drugs 2001, 2 :1093-1096 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Darbepoetin alfa (Amgen). F Locatelli, L Vecchio Current Opinion in Investigational Drugs 2001, 2 :1097-1104 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Overview: Pharmacogenomics of psychiatric disorders - Separating the dreams from the realities. M Briley, C Moret Current Opinion in Investigational Drugs 2001, 2 :1105-1107 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Rodent models of anxiety-like behaviors: Are they predictive for compounds acting via non-benzodiazepine mechanisms? C Belzung Current Opinion in Investigational Drugs 2001, 2 :1108-1111 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Glutamate receptor ligands as anxiolytics. Wojcik E Chojnacka, A Klodzinska, A Pilc Current Opinion in Investigational Drugs 2001, 2 :1112-1119 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Gepirone (Organon). RA Leslie Current Opinion in Investigational Drugs 2001, 2 :1120-1127 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Overview: Changing times: Developing cancer drugs in genomeland. P Workman Current Opinion in Investigational Drugs 2001, 2 :1128-1135 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Mutant p53: The loaded gun. G Selivanova Current Opinion in Investigational Drugs 2001, 2 :1136-1141 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
SU-6668 (SUGEN). D Fabbro, PW Manley Current Opinion in Investigational Drugs 2001, 2 :1142-1148 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Flavopiridol (National Cancer Institute). HK Wang Current Opinion in Investigational Drugs 2001, 2 :1149-1155 (8 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Paper alert M Daneshtalab, T Jones, M Williams, C Darlington, P Smith, S Doggrell, L Hofseth, RE Hurst Current Opinion in Investigational Drugs 2001, 2 :1157-1171 (3 [Abstract ] [Full text ] [PDF ]
Patent selection HAM Mucke Current Opinion in Investigational Drugs 2001, 2 :1172-1175 (3 [Abstract ] [Full text ] [PDF ]
Patent alert WM Brown, HAM Mucke, P Norman Current Opinion in Investigational Drugs 2001, 2 :1176-1190 (3 [Abstract ] [Full text ] [PDF ]
Immunotherapy as an adjunct to highly-active antiretroviral therapy. Corb M Murphey, Fuller D Heydenburg Current Opinion in Investigational Drugs 2001, 2 :1191-1197 (3 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Peptide-lead CXCR4 antagonists with high anti-HIV activity. N Fujii, H Tamamura Current Opinion in Investigational Drugs 2001, 2 :1198-1202 (3 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
AIDSVAX (VaxGen) A Billich Current Opinion in Investigational Drugs 2001, 2 :1203-1208 (3 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
DPC-083 (DuPont Pharmaceuticals) ML Lim Current Opinion in Investigational Drugs 2001, 2 :1209-1212 (3 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Lck inhibitors as a therapeutic approach to autoimmune disease and transplant rejection. JS Kamens, SE Ratnofsky, GC Hirst Current Opinion in Investigational Drugs 2001, 2 :1213-1219 (3 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Everolimus (Novartis) FJ Dumont Current Opinion in Investigational Drugs 2001, 2 :1220-1234 (3 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Overview: 3rd Report of the National Cholesterol Education Program (NCEP III): A switch from dietary modification to risk factor assessment DM Lane Current Opinion in Investigational Drugs 2001, 2 :1235-1236 (3 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Restenosis drug discovery - a formidable task. CQ Meng Current Opinion in Investigational Drugs 2001, 2 :1237-1246 (3 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
VasoCare (Vasogen) F Visioli Current Opinion in Investigational Drugs 2001, 2 :1247-1248 (3 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Mutant P/Q-type calcium channel electrophysiology and migraine. JJ Plomp, AMJM van den Maagdenberg, PC Molenaar, RR Frants, MD Ferrari Current Opinion in Investigational Drugs 2001, 2 :1250-1260 (3 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Development of CGRP antagonists for the treatment of migraine. H Doods Current Opinion in Investigational Drugs 2001, 2 :1261-1268 (3 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Cizolirtine (Laboratorios Dr Esteve). N Monck Current Opinion in Investigational Drugs 2001, 2 :1269-1272 (3 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
LY-293558 (Eli Lilly & Co). I Gilron Current Opinion in Investigational Drugs 2001, 2 :1273-1278 (3 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Overview: STI-571: Current status and future prospects. CA Schiffer Current Opinion in Investigational Drugs 2001, 2 :1279-1281 (3 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Chimeric fusion proteins - Pseudomonas exotoxin-based. RJ Kreitman Current Opinion in Investigational Drugs 2001, 2 :1282-1293 (3 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Chimeric fusion proteins - diphtheria toxin-based. AE Frankel, BL Powell, DA Vallera, DM Neville Current Opinion in Investigational Drugs 2001, 2 :1294-1301 (3 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Thalidomide: An old sedative-hypnotic with anticancer activity? G Gasparini, A Morabito, E Magnani, D Gattuso, B Capaccetti, AM Alberti Current Opinion in Investigational Drugs 2001, 2 :1302-1308 (3 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
hIL-13-PE38QQR (NeoPharm) S Barth Current Opinion in Investigational Drugs 2001, 2 :1309-1313 (3 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
SGN-10 (Seattle Genetics) SV Smith Current Opinion in Investigational Drugs 2001, 2 :1314-1319 (3 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Paper alert M Daneshtalab, T Jones, S Doggrell, Gasparo M de, M Williams, RE Hurst, E Boven Current Opinion in Investigational Drugs 2001, 2 :1321-1333 (9 [Abstract ] [Full text ] [PDF ]
Patent selection HAM Mucke Current Opinion in Investigational Drugs 2001, 2 :1334-1336 (9 [Abstract ] [Full text ] [PDF ]
Patent alert IB Duncan, WM Brown, P Norman, HAM Mucke Current Opinion in Investigational Drugs 2001, 2 :1337-1363 (9 [Abstract ] [Full text ] [PDF ]
Overview: Antifungal combination therapy. AM Sugar Current Opinion in Investigational Drugs 2001, 2 :1364-1365 (9 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Overview: Non-fumigatus species of Aspergillus: Perspectives on emerging pathogens in immunocompromised hosts. TJ Walsh, AH Groll Current Opinion in Investigational Drugs 2001, 2 :1366-1367 (9 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Anti-toxoplasmosis drugs. F Derouin Current Opinion in Investigational Drugs 2001, 2 :1368-1374 (9 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
The treatment of pulmonary aspergilloma. MA Judson, DA Stevens Current Opinion in Investigational Drugs 2001, 2 :1375-1377 (9 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Overview: Nod2, cause of, or contributor to, Crohn's disease. NA Punchard Current Opinion in Investigational Drugs 2001, 2 :1378-1381 (9 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
The role of the gut lymphoid tissue in induction of oral tolerance. F Song, CC Whitacre Current Opinion in Investigational Drugs 2001, 2 :1382-1386 (9 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Anti-inflammatory peptides and proteins in inflammatory bowel disease. M Veljaca Current Opinion in Investigational Drugs 2001, 2 :1387-1394 (9 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
Oprelvekin (Genetics Institute). SV Sitaraman, AT Gerwirtz Current Opinion in Investigational Drugs 2001, 2 :1395-1400 (9 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Alicaforsen (Isis Pharmaceuticals). AT Gerwirtz, S Sitaraman Current Opinion in Investigational Drugs 2001, 2 :1401-1406 (9 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Pharmacological treatment of portal hypertension. J Gonzalez-Abraldes, J Bosch, JC Garcia-Pagan Current Opinion in Investigational Drugs 2001, 2 :1407-1413 (9 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Omapatrilat (Bristol-Myers Squibb). R Tabrizchi Current Opinion in Investigational Drugs 2001, 2 :1414-1422 (9 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
SR-121463 (Sanofi-Synthelabo). A Martinez-Castelao Current Opinion in Investigational Drugs 2001, 2 :1423-1427 (9 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Overview: H3 histamine receptor isoforms: New therapeutic targets in the CNS? PL Chazot, V Hann Current Opinion in Investigational Drugs 2001, 2 :1428-1431 (9 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Cilansetron (Solvay). G Stacher Current Opinion in Investigational Drugs 2001, 2 :1432-1436 (9 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
TAK-637 (Takeda). JB Furness Current Opinion in Investigational Drugs 2001, 2 :1437-1440 (9 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Ezlopitant (Pfizer Inc) S Evangelista Current Opinion in Investigational Drugs 2001, 2 :1441-1443 (9 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Drug properties of second generation antisense oligonucleotides: How do they measure up to their predecessors? SP Henry, RS Geary, R Yu, AA Levin Current Opinion in Investigational Drugs 2001, 2 :1444-1449 (9 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Cellular uptake of antisense oligonucleotides. AM Tari, G Lopez-Berestein Current Opinion in Investigational Drugs 2001, 2 :1450-1453 (9 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
ISIS-3521 (Isis Pharmaceuticals) K Li, J Zhang Current Opinion in Investigational Drugs 2001, 2 :1454-1461 (9 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
GTI-2040 (Lorus Therapeutics) RM Orr Current Opinion in Investigational Drugs 2001, 2 :1462-1466 (9 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
GTI-2501 (Lorus Therapeutics) G-c Tu, X Tu Current Opinion in Investigational Drugs 2001, 2 :1467 (9 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Paper alert M Daneshtaab, S Doggrell, F Barone, RE Hurst, G Damia Current Opinion in Investigational Drugs 2001, 2 :1471-1482 (12 [Abstract ] [Full text ] [PDF ]
Patent selection H Mucke Current Opinion in Investigational Drugs 2001, 2 :1483-1485 (12 [Abstract ] [Full text ] [PDF ]
Patent alert IB Duncan, WM Brown, P Norma, H Mucke Current Opinion in Investigational Drugs 2001, 2 :1486-1515 (12 [Abstract ] [Full text ] [PDF ]
Hepatitis C virus: Prospects for future therapies TC Wilikinson Current Opinion in Investigational Drugs 2001, 2 :1516-1522 (12 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
ISIS-14803 (Isis Pharmaceuticals) GW Witherell Current Opinion in Investigational Drugs 2001, 2 :1523-1529 (12 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Pegasys (Hoffmann-La Roche) DL Barnard Current Opinion in Investigational Drugs 2001, 2 :1530-1538 (12 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Biological activity of tyrosine kinase inhibitors: Novel agents for psoriasis therapy Bassat H Ben Current Opinion in Investigational Drugs 2001, 2 :1539-1545 (12 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Targeting interleukin-2 as a treatment for psoriasis A Salim, R Emerson Current Opinion in Investigational Drugs 2001, 2 :1546-1548 (12 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Targeting phospholipase A2 for the treatment of inflammatory skin diseases JR Burke Current Opinion in Investigational Drugs 2001, 2 :1549-1552 (12 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Immunotherapeutic approaches for the treatment of malignant melanoma Lewandrowski C Curiel, MB Atkins Current Opinion in Investigational Drugs 2001, 2 :1553-1563 (12 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Mechanism of action of thiazolidinediones. M Flemmer, J Scott Current Opinion in Investigational Drugs 2001, 2 :1564-1567 (12 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Current and future treatment strategies for type 2 diabetes: The beta-cell as a therapeutic target. B Tyrberg, F Levine Current Opinion in Investigational Drugs 2001, 2 :1568-1574 (12 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
Pramlintide (Amylin) D Barlocco Current Opinion in Investigational Drugs 2001, 2 :1575-1581 (12 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Parkinson's disease and D(1) dopamine receptors R Mailman, X Huang, DE Nichols Current Opinion in Investigational Drugs 2001, 2 :1582-1591 (12 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
NS-2330 (NeuroSearch) U Thatte Current Opinion in Investigational Drugs 2001, 2 :1592-1594 (12 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
TAK-147 (Takeda) H Mucke Current Opinion in Investigational Drugs 2001, 2 :1595-1599 (12 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Overview - Rational integration of agents directed at novel therapeutic targets into combination chemotherapeutic regimens S Grant, P Dent Current Opinion in Investigational Drugs 2001, 2 :1600-1605 (12 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
The Hsp90 chaperone as a promising drug target. PW Piper Current Opinion in Investigational Drugs 2001, 2 :1606-1610 (12 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Pemetrexed disodium (Eli Lilly) P Norman Current Opinion in Investigational Drugs 2001, 2 :1611-1622 (12 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Alanosine (UCSD) J Yu Current Opinion in Investigational Drugs 2001, 2 :1623-1630 (12 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
ET-743 (PharmaMar/NCI/Ortho Biotech) CF Verschraegen, K Glover Current Opinion in Investigational Drugs 2001, 2 :1631 (12 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Paper alert M Daneshtalab, S Doggrell, F Barone, RE Hurst, G Damia Current Opinion in Investigational Drugs 2001, 2 :1639-1653 (20 [Abstract ] [Full text ] [PDF ]
Patent selection HAM Mucke Current Opinion in Investigational Drugs 2001, 2 :1654-1657 (20 [Abstract ] [Full text ] [PDF ]
Patent alert IB Duncan, WM Brown, P Norman, H Mucke Current Opinion in Investigational Drugs 2001, 2 :1658-1680 (20 [Abstract ] [Full text ] [PDF ]
Combinatorial biosynthesis in microorganisms as a route to new antimicrobial, antitumor and neuroregenerative drugs. CR Hutchinson, R McDaniel Current Opinion in Investigational Drugs 2001, 2 :1681-1690 (20 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Telithromycin (Aventis Pharma). AP Johnson Current Opinion in Investigational Drugs 2001, 2 :1691-1701 (20 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
HMR-3562 (Aventis Pharma). Z Ma, AS Florjancic Current Opinion in Investigational Drugs 2001, 2 :1702-1705 (20 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
T-3811 (Toyama/Bristol-Myers Squibb). R Frechette Current Opinion in Investigational Drugs 2001, 2 :1706-1711 (20 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Targeting the chemokine system for multiple sclerosis treatment. AR Glabinski, RM Ransohoff Current Opinion in Investigational Drugs 2001, 2 :1712-1719 (20 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
Endothelium as a pharmacological target. P d'Alessio Current Opinion in Investigational Drugs 2001, 2 :1720-1724 (20 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Etanercept (Immunex). MK Pugsley Current Opinion in Investigational Drugs 2001, 2 :1725-1731 (20 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
An update of neuroprotectants in clinical development for acute stroke. H Lutsep, W Clark Current Opinion in Investigational Drugs 2001, 2 :1732-1736 (20 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
UK-315716/UK-240455 (Pfizer). AM Capelli, F Micheli Current Opinion in Investigational Drugs 2001, 2 :1737-1739 (20 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
KB-R7943 (Kanebo). GE Billman Current Opinion in Investigational Drugs 2001, 2 :1740-1745 (20 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Overview: A molcule for all occasions. T Alexi Current Opinion in Investigational Drugs 2001, 2 :1740-1745 (20 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Overview: Pro-inflammatory cytokines in cerebrovascular ischemia. K Kumar Current Opinion in Investigational Drugs 2001, 2 :1748-1750 (20 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Cladribine (Ortho Biotech Inc). C Tortorella, M Rovaris, M Filippi Current Opinion in Investigational Drugs 2001, 2 :1751-1756 (20 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Citicoline (Ferrer Internacional). AV Alexandrov Current Opinion in Investigational Drugs 2001, 2 :1757-1762 (20 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Losigamone (Dr Wilmar Schwabe). LJ Willmore Current Opinion in Investigational Drugs 2001, 2 :1763-1766 (20 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Overview: Synthetic gene delivery: Another quest for the Holy Grail? A Rolland Current Opinion in Investigational Drugs 2001, 2 :1767-1769 (20 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
ONYX-015 (Onyx Pharmaceuticals). EEW Cohen, CM Rudin Current Opinion in Investigational Drugs 2001, 2 :1770-1775 (20 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ] [Cited on BioMed Central ]
INGN-201 (Introgen Therapeutics). I Brukner Current Opinion in Investigational Drugs 2001, 2 :1776 (20 [Abstract ] [Full text ] [PDF ] [PubMed ] [Related articles ]
Current Opinion in Investigational Drugs Volumes
previous issue
January
ein